[ANMCO/AICO/AIOM Consensus document: Clinical and management pathways in cardio-oncology].
Luigi Tarantini(Santa Maria Nuova Hospital), Alessandro Inno(Ospedale Sacro Cuore Don Calabria), Francesca Macera(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Daniella Bovelli(Azienda Ospedaliera S.Maria), Maurizio Giuseppe Abrignani, Michele Massimo Gulizia(Ospedale Garibaldi), Donatella Radini(Azienda Sanitaria Universitaria Integrata di Trieste), Luisa De Gennaro(Ospedale San Paolo), Nicola Maurea(Cancer Institute (WIA)), Iris Parrini(A. O. Ordine Mauriziano di Torino), Andrea Di Lenarda(University of Trieste), Irma Bisceglia(Azienda Ospedaliera San Camillo-Forlanini), Angela Beatrice Scardovi(Ospedale di Santo Spirito), Donatella Del Sindaco(Ospedale Regina Margherita), Giulia Russo(University of Catania)
Cited by 3
Related Papers
Truncations of Titin Causing Dilated Cardiomyopathy
|New England Journal of Medicine|2012|1.5k
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
In silico clinical trials: concepts and early adoptions
|Briefings in Bioinformatics|2018|267
Prevalence and Prognostic Impact of Non-Cardiac Co-Morbidities in Heart Failure Outpatients with Preserved and Reduced Ejection Fraction: A Community-Based Study
|European Journal of Heart Failure|2018|174
Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy
|Critical Reviews in Oncology/Hematology|2019|164